zh-twzhen
zh-twzhen

The Company’s 2025Q2 consolidated financial statements have been approved by the Board of Directors

2023

Date

Title

2023-10-03

News-New Cream Could Be Valuable Addition to Diabetic Foot Ulcer Treatment

>
2023-10-02

The Phase 3 MRCT data and the Taiwan real-world cases of the DFU new drug, Fespixon have been accepted for an oral presentation at the 59th EASD Annual Meeting.

>
2023-09-25

Oneness has submitted medical device registration application for Bonvadis to the Egyptian Drug Authority (EDA).

>
2023-09-20

Oneness announces the information about the investor’s conference of 2023 Q3.

>
2023-09-05

The board of directors of the Company approved removal of the noncompete clause for managers.

>
2023-08-31

Oneness has submitted a 510(k) application to the U.S. FDA to expand the intended patient population and add multiple chronic wound indications for Bonvadis.

>
2023-08-15

A Russian patent titled “TREATING IGE-MEDIATED ALLERGIC DISEASES” on FB825 was granted.

>
2023-08-10

The Company’s 2023 Q2 consolidated financial statements have been approved by the Board of Directors.

>
2023-08-09

Oneness was notified today that Bonvadis, the wound care topical cream has obtained import license in South Africa.

>
2023-08-04

Oneness was notified today that Bonvadis, the wound care topical cream has submitted a registration application to the Drug Regulatory Authority of Pakistan (DRAP).

>
2023-08-02

SNS812, a broad-spectrum siRNA for COVID-19 infection, co-developed by Oneness & Microbio (Shanghai) has been agreed by US FDA to proceed with Phase 2 clinical trial.

>
2023-07-20

Oneness Biotech Co., Ltd. receives a European patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101).

>
2023-07-14

Fespixon cream has been approved to be reimbursed by the National Health Insurance

>
2023-07-14

FESPIXON, the new drug in treatment of diabetic foot ulcers has been approved by Malaysia NPRA

>
2023-07-09

Clarification on the media report with regards to the registration approval on Fespixon by Malaysia MOH

>